You can buy or sell ARPO and other stocks, options, ETFs, and crypto commission-free!
Aerpio Pharmaceuticals, Inc. Common Stock, also called Aerpio Pharmaceuticals, is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Read More Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
52 Week High
52 Week Low
Research And Development
Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment
Shares of Aerpio Pharmaceuticals Inc. ARPO, -71.29% plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of improvement over placebo. The stock was the biggest decliner listed on major U.S. exchanges, with volume reaching 5.5 million shares, or about 22 times the full-day average. Meanwhile, the company said the trial of its lead candidate AKB-9778 was found did to be ...
Aerpio Pharmaceuticals (ARPO) Tops Q4 EPS by 2c
Aerpio Pharmaceuticals (NASDAQ: ARPO) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). “We remain on track to report top-line data from our TIME-2b clinical trial before the end of March,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. “We view the study as an important inflection point for Aerpio and expect to use the results to direct the future development of AKB-9778 in non-proliferative diabetic retinopathy and possibly other conditions associated w...
Expected May 14, Pre-Market